Transfer of the sFLT-1 gene in morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response

Clinical Cancer Research

Volumn 11, Issue 6, 2005, Pages 2132-2140

  Schmidt, Kerstin ^a,b   Hoffend, Johannes ^a   Altmann, Annette ^a,b   Strauss, Ludwig G ^b   Dimitrakopoulou Strauss, Antonia ^b   Engelhardt, Britta ^a   Koczan, Dirk ^e   Peter, Jörg ^c   Vorwald, Silke ^a   Eskerski, Helmut ^b   Eisenhut, Michael ^d   Metz, Jürgen ^a   Kimscherf, Ralf ^a   Haberkorn, Uwe ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Clin Coop Unit Nuclear Medicine   (Germany)

^c Dept Biophys Med Radiat Phys ^*  (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; GENE; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULARIZATION; MORPHOMETRICS; MORRIS HEPATOMA; NONHUMAN; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SFLT 1 GENE; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; POSITRON-EMISSION TOMOGRAPHY; PROTEINS; RATS; RATS, NUDE; RETROVIRIDAE; THYMIDINE; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 20144386752     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2133     Document Type: Article

References (63)

1. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
2. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995;177:57-63.
3. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995;55:4140-5.
4. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial cell proliferation in vitro by tumor-associated macrophages. Lab Invest 1984;51:635-42.
5. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
6. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995;67:281-316.
7. Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003;9:2701-10.
8. Mahasreshti PJ, Navarro JG, Kataram M, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001;7:2057-66.
9. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
10. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997;3:1222-7.
11. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996;56:393-401.
12. Cheng SY, Huang HJS, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogeneous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996;93:8502-7.
13. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56:1324-30.
14. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative FLK-1 mutant. Nature 1994;367:576-9.
15. Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998;9:49-58.
16. Kendall RL, CK Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-8.
17. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998;95:8795-800.
18. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998;9:823-33.
19. Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000; 60:2169-77.
20. Mori A, Arii S, Furutani M, et al. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 2000; 7:1027-33.
21. Yang W, Arii S, Mori A, et al. sFlt-1 gene-transfected fibroblasts: a wound-specific gene therapy inhibits local cancer recurrence. Cancer Res 2001;61:7840-5.
22. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993;90:10705-9.
23. Hasumi Y, Mizukami H, Urabe M, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002;62:2019-23.
24. Anderson H, Yap JT, Wells P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003;89:262-7.
25. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiostatic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20:3804-14.
26. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price P. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30.
27. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998;241:161-70.
28. Haberkorn U, Henze M, Altmann A, et al. Transfer of the human sodium iodide symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001;42:317-25.
29. Haberkorn U, Kinscherf R, Kissel M, et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 2003;10:774-80.
30. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-56.
31. Haberkorn U, Altmann A, Kamencic H, et al. Glucose transport and apoptosis after gene therapy with HSV thymidine kinase. Eur J Nucl Med 2001;28:1690-6.
32. 15O-water using compartment and noncompartment analysis. J Nucl Med 2001;42:248-56.
33. Burchert W, Schellong S, van den Hoff J, et al. Oxygen-15-water PET assessment of muscular blood flow in peripheral vascular disease. J Nucl Med 1997;38:93-8.
34. Ohtake T, Kosaka N, Watanabe N, et al. Non-invasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med 1991;32:1432-8.
35. Sharp PE, LaRegina MC. The laboratory rat. Boca Raton, Boston, London, New York, Washington: CRC Press; 1998.
36. Kinscherf R, Wagner M, Kamencic H, et al. Characterization of apoptotic macrophages in atheromatous tissue of humans and heritable hyperlipidemic rabbits. Atherosclerosis 1999;144:33-9.
37. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-25.
38. Yoshimura I, Mizuguchi Y, Miyajima A, et al. Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J Urol 2004;171:2467-70.
39. Ye C, Feng C, Wang S, et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 2004;145:817-22.
40. + cells are the major source of oxidative stress in UV radiation-irradiated skin: possible role in photoaging and photocarcinogenesis. Photochem Photobiol 2003;77:259-64.
41. Sluyter R, Halliday GM. Enhanced tumor growth in UV-irradiated skin is associated with an influx of inflammatory cells into the epidermis. Carcinogenesis 2000;21:1801-7.
42. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
43. Jones MK, Szabo IL, Kawanaka H, et al. von Hippel Lindau tumor suppressor and HIF-1α: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 2002;16:264-6.
44. Ren Y, Tsui HT, Poon RT, et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 2003;107:22-9.
45. Legendre H, Decaestecker C, Nagy N, et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 2003;16:491-504.
46. Akbar SM, Abe M, Murakami H, et al. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett 2001;171:125-32.
47. Nguyen MT, Lue H, Kleemann R, et al. The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J Immunol 2003;170:3337-47.
48. Chiquet-Ehrismann R, Tucker RP. Connective tissues: signalling by tenascins. Int J Biochem Cell Biol 2004;36:1085-9.
49. Latijnhouwers MA, Pfundt R, de Jongh GJ, Schalkwijk J. Tenascin-C expression in human epidermal keratinocytes is regulated by inflammatory cytokines and a stress response pathway. Matrix Biol 1998;17:305-16.
50. Latijnhouwers MA, de Jongh GJ, Bergers M, de Rooij MJ, Schalkwijk J. Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res 2000;292:446-54.
51. Nieto N, Cederbaum AI. Increased Sp1-dependent transactivation of the LAMγ 1 promoter in hepatic stellate cells co-cultured with HepG2 cells overexpressing cytochrome P450 2E1. J Biol Chem 2003;278:15360-72.
52. Collard CD, Montalto MC, Reenstra WR, et al. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001;159:1045-54.
53. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
54. Das DK, Engelman RM, Kimura Y. Molecular adaptation of cellular defences following preconditioning of the heart by repeated ischaemia. Cardiovasc Res 1993;27:578-84.
55. Matejka GL. Expression of GH receptor, IGF-I receptor and IGF-I mRNA in the kidney and liver of rats recovering from unilateral renal ischemia. Growth Horm IGF Res 1998;8:77-82.
56. Weighardt F, Cobianchi F, Cartegni L, et al. A novel hnRNP protein (HAP/SAF-B) enters a subset of hnRNP complexes and relocates in nuclear granules in response to heat shock. J Cell Sci 1999;112:1465-76.
57. Kim BC, Van Gelder H, Kim TA, et al. Activin receptor-like kinase-7 induces apoptosis through activation of MAP kinases in a Smad3-dependent mechanism in hepatoma cells. J Biol Chem 2004; 279:28458-65.
58. Yasuda S, Arii S, Mori A, et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 α and its significance. J Hepatol 2004;40:117-23.
59. Chen W, Lee J, Cho SY, Fine HA. Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 2004;64:3949-57.
60. Ciafre SA, Barillari G, Bongiorno-Borbone L, Wannenes F, Izquierdo M, Farace MG. A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo. Gene Ther 2002;9:297-302.
61. Lund EL, Bastholm L, Kristjansen PEG. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology and angiogenesis in human glioblastoma multiforme. Clin Cancer Res 2000;6:971-8.
62. Mishima K, et al. A peptide derived from the non-receptor binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci U S A 2000;97:8484-9.
63. Bello L, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.